KR102293847B1 - 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 - Google Patents

근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 Download PDF

Info

Publication number
KR102293847B1
KR102293847B1 KR1020187026871A KR20187026871A KR102293847B1 KR 102293847 B1 KR102293847 B1 KR 102293847B1 KR 1020187026871 A KR1020187026871 A KR 1020187026871A KR 20187026871 A KR20187026871 A KR 20187026871A KR 102293847 B1 KR102293847 B1 KR 102293847B1
Authority
KR
South Korea
Prior art keywords
als
masitinib
alsfrs
points
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026871A
Other languages
English (en)
Korean (ko)
Other versions
KR20180125966A (ko
Inventor
알랭 마우지
진-피에르 키넷
콜린 맨스필드
Original Assignee
에이비 사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비 사이언스 filed Critical 에이비 사이언스
Publication of KR20180125966A publication Critical patent/KR20180125966A/ko
Application granted granted Critical
Publication of KR102293847B1 publication Critical patent/KR102293847B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187026871A 2016-03-25 2017-03-24 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 Active KR102293847B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490.3 2016-03-25
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
KR20180125966A KR20180125966A (ko) 2018-11-26
KR102293847B1 true KR102293847B1 (ko) 2021-08-26

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026871A Active KR102293847B1 (ko) 2016-03-25 2017-03-24 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도

Country Status (20)

Country Link
US (1) US10092564B2 (enExample)
EP (1) EP3240538B1 (enExample)
JP (2) JP7250312B2 (enExample)
KR (1) KR102293847B1 (enExample)
CN (1) CN108883108B (enExample)
AU (1) AU2017236177B2 (enExample)
BR (1) BR112018069515A2 (enExample)
CA (1) CA3018635C (enExample)
DK (1) DK3240538T3 (enExample)
EA (1) EA038531B1 (enExample)
ES (1) ES2899929T3 (enExample)
HU (1) HUE057398T2 (enExample)
IL (1) IL261856B (enExample)
MX (1) MX390495B (enExample)
NZ (1) NZ745778A (enExample)
PL (1) PL3240538T3 (enExample)
PT (1) PT3240538T (enExample)
SG (1) SG11201808106YA (enExample)
SI (1) SI3240538T1 (enExample)
WO (1) WO2017162884A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2018045217A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3425390B1 (en) 2016-11-25 2020-12-23 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
CN116139135A (zh) * 2017-03-28 2023-05-23 诺华股份有限公司 治疗多发性硬化的方法
JP6957650B2 (ja) * 2017-05-30 2021-11-02 デシフェラ・ファーマシューティカルズ，エルエルシー 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１−［４−ブロモ−５−［１−エチル−７−（メチルアミノ）−２−オキソ−１，２−ジヒドロ−１，６−ナフチリジン−３−イル］−２−フルオロフェニル］−３−フェニルウレアおよびアナログの使用
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
KR20250057151A (ko) * 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063318A1 (en) 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ATE375342T1 (de) 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
US10238649B2 (en) * 2012-10-04 2019-03-26 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EP3388436B1 (en) * 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063318A1 (en) 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
SI3240538T1 (sl) 2022-02-28
EP3240538A1 (en) 2017-11-08
EA038531B1 (ru) 2021-09-10
PL3240538T3 (pl) 2022-01-31
KR20180125966A (ko) 2018-11-26
JP2019515884A (ja) 2019-06-13
EP3240538B1 (en) 2021-09-29
MX2018011349A (es) 2019-02-07
WO2017162884A1 (en) 2017-09-28
PT3240538T (pt) 2021-12-07
BR112018069515A2 (pt) 2019-04-16
JP7250312B2 (ja) 2023-04-03
AU2017236177A1 (en) 2018-09-20
US10092564B2 (en) 2018-10-09
NZ745778A (en) 2022-07-01
US20180117037A1 (en) 2018-05-03
IL261856A (en) 2018-10-31
CN108883108A (zh) 2018-11-23
DK3240538T3 (da) 2021-12-06
AU2017236177B2 (en) 2022-03-31
CA3018635A1 (en) 2017-09-28
CN108883108B (zh) 2021-08-06
CA3018635C (en) 2023-09-26
SG11201808106YA (en) 2018-10-30
ES2899929T3 (es) 2022-03-15
JP2022037132A (ja) 2022-03-08
IL261856B (en) 2022-04-01
HUE057398T2 (hu) 2022-05-28
MX390495B (es) 2025-03-20
EA201800499A1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
KR102293847B1 (ko) 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
KR20170122777A (ko) 트라디피턴트에 의한 치료 방법
US20140147415A1 (en) Treatment of mastocytosis with masitinib
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US20160263110A1 (en) Use of masitinib for treatment of amyotrophic lateral sclerosis
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2021110737A1 (en) Use of masitinib for the treatment of eosinophilic asthma
WO2016071511A1 (en) Treatment of mast cell activation syndrome (mcas) with masitinib
JP2019517516A (ja) Ｓｍａの新規な処置
US20230321081A1 (en) Masitinib for the treatment of castrate-resistant prostate cancer
JP2015196664A (ja) 関節疾患の治療予防剤
JP2014532684A (ja) Ｖｅｇｆ依存性疾患の治療に使用する２−カルボキサミドシクロアミノウレア誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210302

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210802

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210819

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210820

End annual number: 3

Start annual number: 1

PG1601 Publication of registration